Hematologic

Viewing Page 5 of 7 | Showing Results 41 - 50 of 63

A Phase 1 Dose-Escalation and Cohort-Expansion Study of VLS -101 in Subjects With Hematological Malignancies

Inclusion:Men or women of age ≥18 years.Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2.Presence of measurable B-cell...

Krish Patel, M.D.
  • Swedish Medical Center

A Phase I Study of FT516 as Monotherapy in Relapsed/Refractory Acute Myelogenous Leukemia and in Combination With Monoclonal Antibodies in Relapsed/Refractory B-Cell Lymphoma

KEY INCLUSION CRITERIA:Diagnosis of the following:Regimen A (FT516 monotherapy):Primary Refractory AMLRelapsed AML defined as not in CR after 1 or...

Krish Patel, M.D.
  • Swedish Medical Center

Phase 1/2 FIH Study of REGN5458 (Anti-BCMA x Anti-CD3 Bispecific Antibody) in Patients With Relapsed or Refractory Multiple Myeloma

Key Inclusion Criteria:Eastern Cooperative Oncology Group (ECOG) performance status ≤ 1Confirmed diagnosis of active Multiple Myeloma (MM) by...

William Bensinger, M.D.
  • Swedish Medical Center

A Phase 1/2 Multicenter, Open-label, Study to Determine the Recommended Dose and Regimen, and Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

Inclusion Criteria:Subjects is ≥ 18 years of age and has an Eastern Cooperative Oncology Group (ECOG) performance status score of 0, 1 or...

William Bensinger, M.D.
  • Swedish Medical Center

A Phase 1, Multicenter, Open-label, Dose Finding Study of CC-99712, a BCMA Antibody-Drug Conjugate, in Subjects With Relapsed and Refractory Multiple Myeloma

Inclusion Criteria:Subjects must satisfy the following criteria to be enrolled in the study:Subject (male or female) is ≥ 18 years of age at the...

William Bensinger, M.D.
  • Swedish Medical Center

An Extension Study of Venetoclax for Subjects Who Have Completed a Prior Venetoclax Clinical Trial

Inclusion Criteria:Subject has been enrolled and dosed in an ongoing venetoclax study and continues to tolerate and derive benefit from the study...

John Pagel, M.D.
  • Swedish Medical Center

A Phase I Study with an Expansion Cohort/Randomized Phase II Study of the Combinations of Ipilimumab, Nivolumab and Brentuximab Vedotin in Patients with Relapsed/Refractory Hodgkin Lymphoma

This phase I/II trial studies the side effects and best dose of ipilimumab and nivolumab when given together with brentuximab vedotin, and how well...

Alison Conlin, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Montana, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

Randomized Phase II Trial in Early Relapsing or Refractory Follicular Lymphoma

This randomized phase II trial studies how well obinutuzumab with or without PI3K-delta inhibitor TGR-1202, lenalidomide, or combination...

Gary Goodman, M.D.

The Pacific Cancer Research Consortium clinical trials are offered at multiple locations throughout Oregon, Montana, Washington, Alaska, California, and Idaho. To find a location near you, please contact the Patient Engagement Center at 844-552-2734.

PRISM: A Platform Protocol for the Treatment of Relapsed/Refractory Aggressive Non-Hodgkin's Lymphoma

A Phase 2 Study of the Efficacy and Safety of ACP-196 in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib Therapy

John Pagel, M.D.
  • Swedish Medical Center
Viewing Page 5 of 7 | Showing Results 41 - 50 of 63